Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 9, 2000 - Issue 2
Submit an article Journal homepage
35
Views
9
CrossRef citations to date
0
Altmetric
Drug Evaluation

Pharmacology and clinical experience with amprenavir

Brian Conway University of British Columbia, Viridae Clinical Sciences, 1134 Burrard Street, Vancouver BC, V6Z 1Y8, Canada. [email protected]
&
Stephen D Shafran Division of Infectious Diseases, Department of Medicine, 2E4.11 Walter Mackenzie Health Sciences Centre, University of Alberta, 8440-112 Street, Edmonton AB T6G 2B7, Canada. [email protected]
Pages 371-382 | Published online: 24 Feb 2005

Bibliography

  • Kaposi's sarcoma and pneumocystis pneumonia among homosexual men: New York and California. Morb. Mort. Wkly Rep. (1981) 30:305–308.
  • CARPENTER CCJ, FISCHL MA, HAMMER SM et al.: Antiret-roviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 280:78–86.
  • ••An excellent expert summary document, well referencedand updated yearly.
  • ID Pharma Business Report: Worldwide Antiretroviral Sales (1990–1997).
  • SMITH L: AIDS: the new drug war. Fortune (27 April 1998) 137(8):60.
  • PERELSON AS, NEUMAN AU, MARKOWITZ M, LEONARD JM, HO DD: 11IV-1 dynamics in viva virion clearance rate, infected cell lifespan and viral generation time. Science (1996) 271:1582–1586.
  • ••The seminal article in this groundbreaking field.
  • KATZENSTEIN DA, HAMMER SM, HUGHES MD et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimetre. N Engl. J. Med. (1996) 335:1091–1098.
  • RAE S, RABOUD J, CONWAY B et al: Estimates of the virologic benefit of antiretroviral therapy are both assay and analysis dependent. AIDS (1998) 12:2185–2192.
  • •An important article to clarify the definition of maximal virologic suppression.
  • OPRAVIL M, DEMASI R, HILL A: Prediction of long-term HIV RNA suppression during zidovudine/lamivudine treatment. International Workshop on HIV Drug resistance, Treatment Strategies and Eradication. St. Peters-burg, USA (1997). Abstract 60.
  • GULICK RM, MELLORS JW, HAVLIR D et al.: Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl. J. Med. (1997) 337:734–739.
  • •The first article to confirm the benefits of triple combination therapy.
  • MONTANER JSG, REISS P, COOPER D et al.: A random- ized, double-blinded trial comparing the immunologic and virologic effects of nevirapine, didanosine and zidovudine combinations among antiretroviral naive, AIDS-free, 11IV-1 infected patients with CD4 counts between 200 and 600/mm3. J. Am. Med. Assoc. (1998) 279:930–937.
  • PERELSON AS, ESSUNGER P, CAO Y et al: Decay charac-teristics of HIV-1 -infected compartments during combination therapy. Nature (1997) 387:188–191.
  • FINZI D, HERMANKOVA M, PIERSON T et al.: Identifica-tion of a reservoir for 11IV-1 in patients on highly active antiretroviral therapy. Science (1997) 278:1295–1300.
  • ••A clear demonstration of the inability of current strategies to'cure' HIV infection.
  • TAKAYA S, CONWAY B: Antiretroviral salvage therapy: what to do when all else fails. HIV: Advances in Research & Therapy (1999) 9:23–29.
  • SHULMAN N, KATZENSTEIN D: Second-line therapy: strategies after PI or NNRTI failure. HIV: Advances in Research and Therapy (1999) 9:16–22.
  • Agenerase Product Insert. Glaxo Wellcome Inc., (USA) 1999.
  • PAINTER GR, ST-CLAIR MH, DEMIRANDA P et al: An overview of the preclinical development of the HIV protease inhibitor VX-478 (141W94). 2nd National Conference on Human Retroviruses. Washington, USA (1995). Abstract 167.
  • PAINTER GR, CHING S, REYNOLDS D et al.: 141W94. Drugs Future (1996) 21:347–350.
  • SADLER BM, ELKINE M, HANSON C et al.: The safety and pharmacokinetics of 141W94: an HIV protease inhibitor. 5th International Conference on Clinical Aspects and Treatment of HIV Infection. Copenhagen, Denmark (1995) Abstract.
  • LIVINGSTON DJ, PAZHANISAMY S, PORTER DJT et al.: Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J. Infect. Dis. (1995) 172:1238–1245.
  • TREMBLAY C, MERRILL DP, CHOU TC, HIRSCH MS: Two-and three-protease inhibitor combinations against zidovudine-sensitive and zidovudine-resistant 11IV-1 isolates in vitro. 12th World AIDS Conference. Geneva, Switzerland (1998). Abstract 41201.
  • MOLLA A, CHERNIAVSKIY T, VASAVANONDA S et al.:Synergistic anti-HIV activity of ritonavir and other protease inhibitors in the presence of human serum. 12th World AIDS Conference. Geneva, Switzerland (1998). Abstract 12315.
  • BARRY M, MULCAHY F, MERRY C, GIBBONS S, BACK D:Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin. Pharmacokin. (1999) 36:289–304.
  • •An excellent review, with many good summary tables.
  • SADLER BM, ELKINE M, HANSON C et al.: Pharmacoki-netics of 141W94 after multiple dosing in patients with HIV infection: a preliminary report. Antiviral Res. (1996). Abstract A42.
  • SADLER BM, HANSON CD, CHITTICK GE, SYMONDS WT,ROSKELL NS: Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) Type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob. Agents Chemother. (1999) 43:1686-1692. Amprenavir: a new HIV protease inhibitor. Med. Lett. (1999) 41:64-66. A clear overview of all current data. SADLER B, GILLOTIN C, LOU Y, STEIN D: Effect of demographic, laboratory and clinical covariates on the pharmacokinetics of amprenavir. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (1999). Abstract 375.
  • BAWDON RE: The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir. Infect. Dis. Obstet. Gynecol. (1998) 6:244–246.
  • WOOLLEY J, STUDENBERG S, BOEHLERT C et al.: Cytochrome P-450 isozyme induction, inhibition and metabolism studies with the HIV protease inhibitor, 141W94. 37th Intel-science Conference on Antimicrobial Agents and Chemotherapy. Toronto, USA (1997). Abstract 112.
  • SADLER BM, WALD JA, LOU Y et al.: The single-dose pharmacokinetics of 141W94, zidovudine and lamivu-dine when administered alone and in two- and three-drug combinations. 6th International Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, Germany (1997) Abstract.
  • RAVITCH JR, BRYANT BJ, REESE MJ et al.: In vivo and in vitro studies of the potential for drug interactions involving the antiretroviral 1592 (abacavir) in humans. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (1998) Abstract.
  • MCDOWELL JA, SADLER BM, MILLARD J et al.: Evaluation of potential pharmacokinetic (PK) drug interaction between 141W94 and 1592U89 in HIV+ patients. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997). Abstract A62.
  • SADLER BM, ERON J, WAKEFORD J et al.: Pharmacoki- netics of 141W94 and indinavir (IDV) after single-dose coadministration in HIV-positive volunteers. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, USA (1997). Abstract A554.
  • SADLER B, GILLOTIN C, CHITTICK GE et al.: Pharmacoki- netic drug interactions with amprenavir. 12th World AIDS Conference. Geneva, Switzerland (1998). Abstract 12389.
  • KEMPF DJ, MARSH KC, KUMAR G et al: Pharmacokinetic enhancement of inhibitors of the human immunodefi-ciency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. (1997) 41:654–660.
  • •An early article describing a key principle underlying the design of combination antiretroviral therapy.
  • DECKER CJ, LAITINEN LM, BRIDSON GW, RAYBUCK SA, TUNG RD, CHATURVEDI PR: Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J. Pharm. ScL (1998) 87:803–807.
  • PISCITELLI S, VOGEL S, SADLER B et al.: Effect of efavirenz (DMP266) on the pharmacokinetics of 141W94 in HIV-infected patients. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (1998) Abstract.
  • POLK RE, ISRAEL DS, PASTOR A et al.: Pharmacokinetic (PK) interaction between ketoconazole (KCZ) and the 111V protease inhibitor 141W94 after single dose administration in normal volunteers. 37th Intel-science Conference on Antimicrobial Agents and Chemotherapy. Toronto, USA (1997) Abstract.
  • KAUL DR, CINTI SK, CARVER PL, KAZANJIAN PH: HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications. Pharmacotherapy (1999) 19:281–298.
  • PARTALEDIS JA, YAMAGUCHI K, TISDALE M et al.: In vitro selection and characterization of human immunodefi-ciency virus Type 1 (111V-1) isolates with reduced sensitivity to hydroxyethyl-amino sulfonamide inhibitors of 11IV-1 aspartyl protease. J. Vim]. (1995) 69:5228–5235.
  • TISDALE M, MYERS RE, MASCHERA B et al.: Cross-resistance analysis of human immunodeficiency virus Type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. (1995) 39:1704–1710.
  • TISDALE M, MYERS RE, SNOWDEN W: Genotypic and phenotypic analysis of 111V from patients on ZDV/3TC/amprenavir combination therapy. 12th World AIDS Conference. Geneva, Switzerland (1998). Abstract 32312.
  • PATICK AK, DURAN M, CAO Y et al.: Genotypic and phenotypic characterization of human immunodefi-ciency virus Type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimi-crob. Agents Chemother. (1998) 42:2637–2644.
  • •An outline of the possible rationale for the sequential use of protease inhibitors in clinical practice.
  • CRAIG C, RACE E, SHELDON J et al.: HIV protease genotype and viral sensitivity to HIV protease inhibi-tors following saquinavir therapy. AIDS (1998) 12:1611–1618.
  • •An outline of the possible rationale for the sequential use of protease inhibitors in clinical practice.
  • YVON A, DESCAMPS D, DELAUGERRE C et al.: Amprenavir genotypic resistance profile in protease inhibitor multi-experienced patients. 3rd International Workshop on HIV Drug Resistance & Treatment Strategies San Diego, USA (1999). Abstract 42.
  • TISDALE M, MYERS RE, T-KHALED Al, SNOWDEN W: HIVdrug resistance during clinical studies with the protease inhibitor amprenavir. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (1999). Abstract 118.
  • ROSS L, KELLEHER D, LANIER R, MELLORS J: 11IV-1genotype and viral response to Ziagen (abacavir) and protease inhibitors in ART naive adults. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (1999). Abstract 115.
  • BART PA, RIZZARDI GP, GALLANT S: Combination abacavir (1592, ABC)/ amprenavir (141W94) therapy in 11IV-1 infected antiretroviral naive subjects with CD4+ counts 400 cells/4 and viral load 5000 copies/ml. 12th World AIDS Conference. Geneva, Switzer-land (1998). Abstract 286/12204.
  • KELLEHER D, MELLORS J, LEDERMAN M et al.: Activity ofabacavir (1592, ABC) combined with protease inhibi-tors (PI) in therapy naive patients. 12th World AIDS Conference. Geneva, Switzerland (1998). Abstract 12210.
  • MELLORS J, LEDERMAN M, HAAS D et al.: Durable activityof Ziagen (1592, ABC) combined with protease inhibi-tors (PI) in therapy naive adults. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (1999). Abstract 625.
  • KELLEHER D, LEDERMAN M, MELLORS J: Early and sustained changes in lymphocyte sub-populations during abacavir (ABC) and PI therapy. 12th World AIDS Conference. Geneva, Switzerland (1998). Abstract 12213.
  • BART PA, RIZZARDI GP, GALLANT S et al.: Combination abacavir (1592, ABC)/ amprenavir (141W94) therapy in 11IV-1 infected antiretroviral naive subjects with CD4+ counts 400 cells/uL and viral load 5000 copies/ml. 6th Conference on Retroviruses and Opportun-istic Infections. Chicago, USA (1999). Abstract 626.
  • ERON J, HAUBRICH R, RICHMAN D et al.: Preliminary assessment of 141W94 in combination with other protease inhibitors. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (1998) Abstract.
  • THE 141W94 INTERNATIONAL STUDY GROUP: Prelimi-nary data on the safety and antiviral efficacy of the novel protease inhibitor 141W94 in HIV-infected patients with 150 to 400 CD4+ cells/mm3. 36th Intel-sci-ence Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996) Abstract.
  • MURPHY RL, GULICK RM, DEGRUTTOLA V et al.: Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. J. Infect. Dis. (1999) 179:808–816.
  • •A very controversial study for its use of Amprenavir monotherapy, but a clear demonstration of the benefit of amprenavir-based triple drug therapy in a clinical trial.
  • ADKINS JC, FAULDS D: Amprenavir. Drugs (1998) 55:837–842.
  • ••An excellent source of overall information on amprenavir. HAUBRICH R: Phase 2 study of amprenavir, a novel protease inhibitor, in combination with zidovu-dine/3TC. 12th World AIDS Conference. Geneva, Switzer-land (1998). Abstract 12321.
  • KOST R, CAO Y, ZHANG L et al.: Potent, durable combination therapy with abacavir, amprenavir and ZDV/3TC in subjects acutely and chronically infected with 11IV-1. 6th Conference on Retroviruses and Opportun-istic Infections. Chicago, USA (1999). Abstract 639.
  • AIT-KHALED M, RAKIK A, THOMAS D et al. 11IV-1 baseline genotype/phenotype and virological response following salvage therapy with Ziagen (abacavir, ABC) amprenavir (APV) and Sustive% 6th
  • Conference on Retroviruses and Opportunistic Infections.. Chicago, USA (1999). Abstract 133.
  • YOGEV R, CHURCH J, FLYNN P et al: Pediatric trial of combination therapy including the protease inhibitor amprenavir (APV). 6th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (1999). Abstract 430.
  • PEDNEAULT L, FETTER A, HANSON C, WILSON J, NACCI L, MILLARD J: Amprenavir: Review of overall safety profile. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (1999). Abstract 386.
  • FDA TALK PAPERS: FDA approves amprenavir for HIV infection. (16 April 1999).
  • MOYLE G: Amprenavir: a viewpoint. Drugs (2998) 55:843–844.
  • HIRSCH MS, CONWAY B, RICHMAN D et al.: Antiretro-viral drug resistance testing in adults with HIV infection. J. Am. Med. Assoc. (1998) 279:1984–1991.
  • ••An excellent expert summary document, well referencedand updated yearly.
  • FALCOZ C, JENKINS JM, BYE C et al.: Single-dose safety and pharmacokinetics of GW433908, a prodrug of amprenavir (141W94, APV), administered as an oral liquid formulation to healthy male subjects. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, USA (1999). Abstract 918.

Websites

  • http://www.cdc.gov/nchstp/hiv_aids/stats/internat.htm Basic Statistics, International Projections/Statistics. CDC-NCHSTP, Divisions of HIV/AIDS Prevention. (Last updated 1 December 1998).
  • http://www.hwcweb.hwc.ca/hpb/lcdc/publicat/aids/aic04-99/aid99e_d.htm HIV and AIDS in Canada, Health Canada Surveillance Report to 31 December 1998.
  • http://www.cdc.gov/nchstp/hiv_aids/graphics.htm HIV/AIDS Surveillance Report. CDC-NCHSTP - Divisions of HIV/AIDS Prevention. (Last updated 1 December 1998).
  • http://www.thebody.com/poz/surviva1/6_98/enemy.htm SILVERSTEIN K: Sleeping with the enemy. POZ. Brian ConwayII & Stephen D Shafran2

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.